Overview

The Repatriation Medical Authority Instrument No. 122 of 2011 amends the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, as part of the legislative effort to address the medical condition of neoplasm of the pituitary gland. This instrument was enacted to update the Statement of Principles concerning this condition, reflecting new medical understandings and evidence. The Authority, acting under subsections 196B(3) and (8) of the Veterans’ Entitlements Act 1986, determined the amendment following an investigation advertised on 12 May 2010, which aimed to gather input from relevant organisations and experts. Despite invitations for submissions, none were received, leading the Authority to finalise the instrument on 21 June 2011. The objective was to refine the medical criteria concerning the condition, ensuring that the legislative framework accurately reflects current medical knowledge and appropriately supports affected veterans.

Scope and Application

The Repatriation Medical Authority Instrument No. 122 of 2011 amends Statement of Principles Instrument No. 43 of 2004 concerning neoplasm of the pituitary gland, applying to veterans who have or have had such conditions. This legislation is an extension of the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, and its application is confined to those who are eligible for benefits under these acts. The instrument specifically modifies the factors associated with the onset and worsening of neoplasm of the pituitary gland, particularly regarding 'bilateral adrenalectomy'. This amendment provides a more precise delineation of the medical conditions and their contributing factors that may affect the eligibility for veterans' benefits. The changes come into effect from a date specified in accordance with the Legislative Instruments Act 2003. There are no stated exclusions or exemptions within this instrument, and it applies nationally as it is an instrument under Commonwealth legislation. The Authority sought submissions from relevant stakeholders during the investigation phase but received none for consideration.

Key Provisions

The Repatriation Medical Authority Instrument No. 122 of 2011 amends Statement of Principles Instrument No. 43 of 2004 regarding neoplasm of the pituitary gland. It makes several changes to the Statement of Principles, including deleting the existing onset and worsening factors concerning 'bilateral adrenalectomy' and inserting a new factor 5(a) relating to the same. The existing factor 5(c) is re-numbered as 5(b), and clause 6 is replaced to reflect these changes. This Instrument, as determined under subsection 196B(3) & (8) of the Veterans' Entitlements Act 1986 (VEA), provides a clear and updated statement of principles concerning the condition, ensuring that the legislation remains relevant and accurate. The obligations imposed by this Instrument on the parties or entities it governs are primarily related to the implementation and application of the updated Statement of Principles. The Repatriation Medical Authority is responsible for ensuring that the new provisions are correctly incorporated into the existing framework and that any relevant changes are communicated to the relevant stakeholders, including veterans, service personnel, and their dependants. The Repatriation Commission and other relevant entities must adhere to the updated principles when assessing claims and providing benefits to affected individuals. This ensures consistency and fairness in the application of the legislation and maintains the integrity of the compensation and rehabilitation processes. The Instrument also includes provisions for determining the date of effect for the amendment, in accordance with subsection 12(1)(a) of the Legislative Instruments Act 2003. This allows for a clear and defined timeline for the implementation of the changes, ensuring that all parties are aware of when the updated principles come into force. The Repatriation Medical Authority is required to advertise the intention to undertake an investigation and invite submissions from relevant organisations and individuals. Although no submissions were received for consideration by the Authority, the process ensures transparency and allows for any necessary feedback or concerns to be addressed before the final determination of the Instrument. In terms of offences, penalties, or consequences for breach, the Instrument does not explicitly outline any specific civil or criminal consequences. However, the Repatriation Medical Authority and relevant entities must ensure compliance with the updated Statement of Principles when assessing claims and providing benefits. Failure to adhere to the new provisions could result in legal challenges or disputes, potentially leading to financial or reputational consequences for the Authority or the relevant entities. It is essential that all parties involved in the administration of the legislation remain aware of their obligations and responsibilities to avoid any potential issues or breaches.